BHCM
EW icon

Brevan Howard Capital Management’s Edwards Lifesciences EW Stock Holding History

Brevan Howard Capital Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.65M Sell
33,116
-35,564
-52% -$2.93M 0.02% 451
2025
Q4 		$5.89M Buy
68,680
+22,408
+48% +$1.84M 0.06% 204
2025
Q3 		$3.6M Sell
46,272
-33,100
-42% -$2.59M 0.02% 328
2025
Q2 		$6.21M Buy
79,372
+73,154
+1,176% +$5.46M 0.04% 299
2025
Q1 		$451K Sell
6,218
-5,649
-48% -$404K ﹤0.01% 751
2024
Q4 		$879K Buy
11,867
+8,712
+276% +$610K 0.01% 461
2024
Q3 		$208K Sell
3,155
-27,034
-90% -$1.96M ﹤0.01% 981
2024
Q2 		$2.79M Buy
30,189
+19,870
+193% +$1.76M 0.02% 155
2024
Q1 		$986K Buy
10,319
+4,469
+76% +$375K 0.01% 275
2023
Q4 		$446K Buy
+5,850
New +$407K 0.01% 533

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Brevan Howard Capital Management's EW Position: Q1 2026 in Review

Brevan Howard Capital Management reduced its Edwards Lifesciences (EW) stake by 52% in Q1 2026, selling an estimated $2.93M and leaving 33,116 shares worth $2.65M. The position accounts for 0.02% of the portfolio, ranked #451.

Brevan Howard Capital Management first reported a position in EW in Q4 2023 and has held it in 10 quarters since. The position peaked at $6.21M in Q2 2025. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Brevan Howard Capital Management held 33,116 shares of Edwards Lifesciences worth $2.65M as of Q1 2026.
  • Brevan Howard Capital Management sold 35,564 Edwards Lifesciences shares in Q1 2026, an estimated $2.93M.
  • Edwards Lifesciences made up 0.02% of Brevan Howard Capital Management's portfolio in Q1 2026, its #451 holding.
  • Brevan Howard Capital Management first reported a position in Edwards Lifesciences in Q4 2023 and has held it in 10 quarters since.
  • Brevan Howard Capital Management's Edwards Lifesciences position peaked at $6.21M in Q2 2025.
  • 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.